Personalis, Inc. (PSNL) · Oct 6, 2026 · Acquisition
HSR cleared — HSR waiting period expired at 11:59 p.m. ET on October 2, 2026
Personalis’ acquisition by Tempus clears the antitrust waiting period, removing one closing condition while shareholder approval and other deal conditions remain.
Personalis is a precision-oncology diagnostics company focused on tumor-informed minimal residual disease testing and recurrence monitoring; Tempus is acquiring it to bring that capability inside its broader AI-enabled precision-oncology platform.
One closing hurdle is gone. The HSR antitrust waiting period expired at 11:59 p.m. Eastern time on October 2, removing the standard federal antitrust review condition from the path to closing. 〔0〕
This advances the deal, but does not change its economic terms or make closing certain. The transaction still requires Personalis stockholder approval and satisfaction or waiver of the remaining closing conditions. 〔1〕
The update is procedural rather than a fresh strategic surprise. The merger was announced on July 20, 2026, and the HSR review was a known step in the transaction process, so this filing mainly confirms steady execution rather than adding value, new operating data, or revised deal terms.
Bottom line: The Tempus acquisition moves one step closer to completion, but this is a routine milestone, not a completed transaction or a new improvement to Personalis’ standalone business story.
Personalis shareholder vote; meeting date still to be announced
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!